BioSpace News Archive

Amniotic membrane (AM), also known as amnion, is a thin inner layer of the fetal placenta which surrounds the baby during pregnancy.

Hyperlipidemia or high cholesterol refers to condition that has too many lipids in the blood. Hyperlipidemia can be inherited however, unbalanced diet and little physical activity could result in hyperlipidemia.

Rise in incidences of kidney diseases and prevalence of lifestyle and chronic diseases led to adoption of different dialysis treatments.

Sumitomo Pharma Oncology, Inc. announced it will present new clinical and preclinical data on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research Annual Meeting, held April 8-13, 2022, in New Orleans, LA.

Significant surge in the prevalence of numerous diseases coupled with the increase in geriatric population across the globe is expected to increase the demand for filgrastim in the coming years.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that management will present at the following upcoming virtual investor conferences.

Surface Oncology announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research Annual Meeting 2022, being held in New Orleans, April 8-13, 2022.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced that the company will present a poster at the upcoming American Association for Cancer Research 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

HotSpot Therapeutics, Inc. announced the presentation of additional pre-clinical data on the Company’s Casitas B-lineage lymphoma proto-oncogene program in a poster presentation at the American Association for Cancer Research Annual Meeting 2022.